alagebrium has been researched along with Fibrosis in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bierhaus, A; Cooper, ME; Gray, SP; Jandeleit-Dahm, KA; Jiaze, L; Pickering, R; Soro-Paavonen, A; Thomas, MC; Tikellis, C; Tsorotes, D; Watson, AM; Wong, B | 1 |
Burns, WC; Cooper, ME; Forbes, JM; Founds, HW; Jerums, G; Thallas, V; Thomas, MC | 1 |
Cooper, ME | 1 |
1 review(s) available for alagebrium and Fibrosis
Article | Year |
---|---|
Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
Topics: Animals; Atherosclerosis; Blood Glucose; Cardiomyopathies; Cardiovascular Agents; Diabetic Angiopathies; Diabetic Nephropathies; Fibrosis; Glycation End Products, Advanced; Humans; Myocardium; Thiazoles | 2004 |
2 other study(ies) available for alagebrium and Fibrosis
Article | Year |
---|---|
Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.
Topics: Albuminuria; Animals; Apolipoproteins E; Diabetes Mellitus, Experimental; Fibrosis; Glomerular Mesangium; Glomerulonephritis; Glycation End Products, Advanced; Male; Mice; Mice, Knockout; Nephritis; Oxidative Stress; Quinapril; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Tetrahydroisoquinolines; Thiazoles | 2012 |
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
Topics: Albuminuria; Animal Population Groups; Animals; Blood Pressure; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Glycation End Products, Advanced; Immediate-Early Proteins; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kidney; Kinetics; Lysine; Models, Biological; Rats; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Solubility; Thiazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tyrosine | 2003 |